We may only be two months into 2025, but Alltrna CEO Michelle Werner sees many reasons for 𝗵𝗼𝗽𝗲 in rare diseases this year and beyond. Much of that hope comes from rapid advancements in technology and new treatment modalities, from gene editing and gene therapy to new #tRNA

Catch the full conversation here:

🚀 Partnering for Innovation – A thought-provoking discussion led by Paul Biondi of Flagship Pioneering at the Axiom Crossroads Summit. Catch the full conversation here: https://t.co/Un0kQmIqZ2 #HealthcareInnovation #Collaboration #AxiomSummit #AxiomThinkTank

Get ready for an insightful session at the Axiom Crossroads Summit, led by Biren Amin, Managing Director of @Piper_Sandler , on the Outlook on Capital Markets. Discover key trends and strategies that are shaping the investment landscape in healthcare. https://t.co/SuIb1Dr7rg

Thrilled to share that @PaulBiondi9 , General Partner of @FlagshipPioneer and President of Pioneering Medicine will be leading an insightful discussion at the Axiom Crossroads Summit in Boston next week! Register here: https://t.co/SuIb1Dr7rg

Don’t miss out on this chance to deepen your understanding and engage with top minds in oncology. Secure your spot now - registration is required! 📌 REGISTER HERE for Post #ESMO2024 Townhall at https://t.co/D5YpRwe9U6

Women at Axiom drive innovation with unique perspectives, leadership, and collaboration. Their impact bridges past achievements to future aspirations, embodying empowerment and inclusion. #InspireInclusion #AxiomThinkTank #IWD #InternationalWomensDay

From now through #GivingTuesday, we're highlighting some of the NJ nonprofits that could benefit from your support, as featured in our 2023 Giving Guide 💙 Click through to learn more about the @AxiomREACH Foundation: https://t.co/mRCXFwm7WK

Join us at ESMO 2023 booth #753 for a chance to meet the Axiom Thinkers, gain invaluable Oncology insights, one-on-one sessions with luminaries, and explore strategic partnerships. We look forward to seeing you at ESMO 2023! Madrid, Spain 20–24 October 2023 #ESMO23 #ThinkTank

We are excited to announce publication of our first Axiom Assessment is now available for purchase. This analysis reviews key trends and players in the ADC, antibody, and T cell engager oncology pipeline. Come check it out! Purchase an Axiom Assessment: https://t.co/eboWyx3ztw

Axiom U's first week was inspiring, gathering of brilliant minds, dedicated to fostering innovation, intellectual curiosity, and meaningful connections at the esteemed #AxiomTable #AxiomLife #AxiomThinkTank #AxiomU

The Axiom think tank table is all set to welcome the new 2023 cohort! #AxiomThinkTank #Cohort2023 #TheTable

The Axiom thinkers send our congratulations to @Sarepta Therapeutics on the FDA's approval of their groundbreaking gene therapy for Duchenne Muscular Dystrophy. While there is still a long way to go, we celebrate each step forward on this journey. Keep pushing boundaries!

Join us for an inspiring gathering of top-notch experts from prestigious academic centers and visionary leaders from the biopharma industry. Together, we will engage in powerful discussions that explore the ever-evolving landscape of cancer care & work toward bridging disparities

Antibody drug conjugates are one of the most exciting areas in oncology today, but the mechanisms of resistance are varied and complex. How might resistance to an ADC impact a patient’s future therapeutic options? #AxiomThinkTank #therapeutic #oncology

2022 saw advances in use of targeted and IO therapies for GI cancers. Check out Axiom's latest white paper to learn more about the readout of pivotal clinical trials, and nuances in treatment of gastric and pancreatic cancers. Read here: https://t.co/Y6SugysLkn #oncology #Cancer

Fresh off the press - our annual report is out. Look out for your paper copy in your mailbox. It has been a monumental journey last year. We could not have done it without you! Thank you! #axiomthinktank #annualreport #freshoffthepress #growth #journey #oncology

Axiom’s latest white paper reviewing 2022 advances in GU cancers here: https://t.co/9W9hvyLENO We are eagerly awaiting key trial results for new approaches in 2023. #AxiomThinkTank

Axiom continues to thrive and grow into 2023. We recently held an open house to showcase the Think Tank for prospective candidates. We are continuing to hire - Life Science Specialist candidates are encouraged to apply at https://t.co/GMG1BTkv1t #hiringnow #lifescience #openhouse

Join our discussion on updates seen at ASCO GU 2023. We analyze some of the most anticipated read outs in RCC, bladder, and prostate cancers and consider what this data means for physicians and patients. Listen on Spotify https://t.co/HqxGVAQuPd #podcast #thinktank #catalyst